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Background: Gastric neuroendocrine carcinoma (G-NEC) is a rare, highly malignant tumor that exhibits aggressive
growth leading to vascular invasion, distant metastasis and extremely poor prognosis. We studied the
clinicopathological findings of seven patients at our institute to better under this disease.
Methods: Seven cases of G-NEC were identified among 1,027 cases of gastric carcinoma that underwent
gastrectomy at Kansai Rousai Hospital between 2002 and 2010. We studied the pathological and
immunohistochemical features of gastric neuroendocrine carcinomas at both the primary site and metastatic lymph
nodes.
Results: The mean patient age was 73 years (range 63 to 86 years). There were no females in this series. The final
staging was Stage I in one case, Stage II in two, Stage III in two and Stage IV in two. A total of 31 metastatic lymph
nodes were found in these patients. This study revealed that the ratio of neuroendocrine cells was similar between
the primary and metastatic sites, which tended to show the same expression patterns of neuroendocrine markers.
Conclusions: Metastatic lymph nodes showed heterogeneous immunohistochemical expression patterns similar to
the primary sites. G-NEC is far advanced at diagnosis and rapidly reaches the lymph nodes retaining its
heterogeneity, carrying a worse prognosis than common gastric cancer.
Mini abstract: G-NEC grows rapidly and metastasizes to the lymph nodes, retaining its pathological and
immunohistochemical heterogeneity even at the metastatic sites.
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Gastric neuroendocrine carcinoma (G-NEC) is a rare
tumor (0.1 to 0.2% of all gastric carcinomas) with highly
malignant biological behavior exhibiting aggressive
growth that leads to vascular invasion, distant metastasis
and extremely poor prognosis. The 2010 WHO classifi-
cation defines well-differentiated endocrine tumors/car-
cinomas as neuroendocrine tumors (NETs), and poorly
differentiated endocrine carcinomas as neuroendocrine
carcinomas (NECs). Compared with well-differentiated
gastric NETs, G-NECs have highly malignant behavior* Correspondence: stamura@kanrou.net
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reproduction in any medium, provided the orand poor prognosis, but their prognostic markers and
therapeutic strategies have not yet been defined.
A definite diagnosis of G-NEC is provided by immu-
nohistochemical examination with neuroendocrine mar-
kers, such as synaptophysin (SYN), chromogranin A
(CGA), CD56 and neuron-specific enolase (NSE). It has
been proposed that care should be exercised in diagnosis
because of the variation shown by G-NECs in both
histological morphology and immunohistochemical ex-
pression. However, no reports have investigated the rela-
tionship between the expression pattern at the primary
site and that at the metastatic sites as to both histo-
logical morphology and immunohistochemical expres-
sion. In this study, we examined the primary tumors and
all metastatic lymph nodes, and reviewed the associationral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ical examination.Methods
Patients and specimens
Seven cases of G-NEC were identified among 1,027 cases
of gastric carcinoma that underwent gastrectomy at Kansai
Rousai Hospital between 2002 and 2010 (0.68%). All
patients gave written informed consent for clinicopatholo-
gical evaluation.
Table 1 lists the clinicopathological characteristics of
these patients. The median age was 73 years (range 63 to
86 years). There were no females in this series. All patients
underwent gastrectomy with regional lymph node dissec-
tion, and in Case 4, additional liver resection was per-
formed for synchronous liver metastasis.Immunohistochemical staining
All resected stomachs and lymph nodes were fixed in 10%
neutral formalin, and then, the entire tumor was step-cut
to a width of 4 to 5 mm. Specimens were embedded in par-
affin, cut into 4-μm sections and stained with hematoxylin
and eosin. An immunohistochemical procedure using the
EnVision system (DakoCytomation, Glostrup, Denmark)
was employed as previously established. Immunohisto-
chemical staining was examined in all blocks of the max-
imum divided surface of the primary site and all blocks of
the metastatic lymph nodes in each case. We reviewed the
histology of the tumor on hematoxylin and eosin stains
and evaluated the expression of SYN, CGA, CD56 and
NSE. We examined not only the primary tumors but also
236 lymph nodes, from which we identified 31 metastatic
lymph nodes derived from five patients. The immunohisto-
chemical expression for each antibody was defined as fol-
lows: − (<5%), 1+ (5 to 9%), 2+ (10 to 49%) and 3+ (over
50%). The ratio of the tumor area with positivity of each
marker was evaluated throughout the maximum dimension
of the primary tumors and metastatic lymph nodes.Table 1 Patients’ characteristics
Patient No. Age Location Gross type Tumor size (cm)
1 63 L 3 13
2 71 M 2 2
3 71 M 3 13
4 86 M 2 3
5 74 M 2 9
6 69 L 3 3
7 77 M 5 6
NEC, neuroendocrine carcinoma; por1, poorly differentiated adenocarcinoma, solid
Resectability; tub2, moderately differentiated tubular adenocarcinoma.Positivity was defined as a dimension ratio of expression
exceeding 10% (over 2+). The following antibodies were
used: anti-synaptophysin and anti-CD56 purchased from
Novocastra Laboratories Ltd. (Newcastle upon Tyne, UK),
and anti-chromogranin A and anti-NSE purchased from
DakoCytomation (Glostrup, Denmark). The Ki67 labeling
index was also estimated in the block including the deepest
part of the primary tumor.Results
Gross findings and staging
Five tumors were located in the middle of the stomach,
and the remaining two were in the lower stomach (Table 1).
One case was a T1b (submucosa) tumor, four cases were
T3 (subserosa), one was T4a (penetration of serosa) and
one was T4b (invasion to adjacent structures) (Table 2).
Lymph node metastasis was found in five cases. The final
staging was Stage IA in one case, Stage IIA in one, Stage
IIB in one, Stage IIIA in one, Stage IIIB in one and Stage
IV in two, according to the seventh American Joint Com-
mittee on Cancer (AJCC) TNM staging classification. The
tumors had grown to a median size of 6 cm (range 2 to 13
cm) in the greatest dimension. Grossly, the tumor was
Type 3 in three cases, Type 2 in three and Type 5 in one.Expression of immunohistochemical staining between the
primary and metastatic sites
Only three cases were correctly diagnosed as G-NEC pre-
operatively. We summarized the varied histological pat-
terns of the primary tumors and lymph nodes in Table 3.
According to the WHO classification, five of the seven
tumors were large-cell subtypes and the others were small-
cell subtypes. They were classified into five pure neuroen-
docrine carcinomas and two tumors combined with
adenocarcinoma. We examined a total of 236 lymph nodes
obtained from seven patients. Among them, 31 positive
nodes included 12 nodes showing pure adenocarcinoma,
3 showing both adenocarcinoma and neuroendocrinePreoperative diagnosis Operation R
tub2 Distal gastrectomy R2
por1> tub2 Total gastrectomy R0
NEC Distal gastrectomy R1
tub2> por1> por2 Distal gastrectomy+Hepatectomy R1
NEC Distal gastrectomy R0
tub2 Distal gastrectomy R0
NEC Distal gastrectomy R0
type; por2. poorly differentiated adenocarcinoma, non-solid type; R,
Table 2 Clinicopathological findings of primary tumor and resected lymph node
Pt
No
Pathological Stage Metastatic ratio of dissected
lymph nodes




n (%) n (%) n (%) n (%)
1 T4b N3a M0 H0 P0 CY1 IV 8/16 (50) 0 (0) 0 (0) 8 (100)
2 T3 N2 M0 H0 P0 CY0 IIIA 5/26 (19) 0 (0) 0 (0) 5 (100)
3 T3 N0 M0 H0 P0 CY0 IIA 0/42 (0) - - -
4 T3 N1 M0 H1 P0 CY0 IV 1/31 (3) 0 (0) 0 (0) 1 (100)
5 T3 N1 M0 H0 P0 CY0 IIB 2/52 (4) 0 (0) 0 (0) 2 (100)
6 T4a N3b M0 H0 P0 CY0 IIIC 15/25 (60) 12 (80) 3 (20) 0 (0)
7 T1b N0 M0 H0 P0 CY0 IA 0/44 (0) - - -
Uchiyama et al. World Journal of Surgical Oncology 2012, 10:115 Page 3 of 5
http://www.wjso.com/content/10/1/115carcinoma, and 16 showing pure neuroendocrine carcin-
oma. While the cases with pure NEC had lymph node me-
tastasis of pure NEC (for example, Case 1 shown in
Figures 1 and 2), the two remaining cases with both adeno-
carcinoma cells and neuroendocrine carcinoma cells had
varied lymph node metastasis. Case 4 had pure NEC, and
Case 6 had both pure adenocarcinoma nodes and con-
comitant nodes. In addition, we verified the primary and
lymph node subtypes by staining for neuroendocrine mar-
kers, and all primary tumors were strongly stained by SYN
and CD56. Most cases showed varied expression patterns
that were similar in both the primary and metastatic sites.
The accordance of positivity between the primary sites and
lymph nodes was extremely high: 80% in SYN, 100% in
CGA, 60% in CD56 and 80% in NSE. Furthermore, the
Ki67 labeling index was high, over 20% in all cases.
Clinical course
Adjuvant chemotherapy, including S-1, was introduced










SYN CGA CD56 N
1 SC 100 3+ - 3+ 3
2 LC 100 3+ 3+ 2+ 1
3 LC 100 3+ - 2+ 3
4 LC> tub2 90 3+ 3+ 3+ -
5 LC 100 3+ - 3+ -
6 LC> tub2> por1 60 3+ 3+ 3+ 1
7 SC 100 3+ - 2+ 3
Expression positivity was defined as follows; - (<5%), 1+ (5 to 9%), 2+ (10 to 49%),
power fields; LC, large cell; NSE, neuron-specific enolase; SC, small cell; SYN, synaptotreatment duration was 8.1 months (range 0.9 to 24.5
months). During the treatment course, there were two
recurrences (Cases 1 and 4) and one death three months
after incurative surgery (Case 1). The major site of re-
lapse was the liver, followed by the peritoneum. Chemo-
therapy was introduced after liver recurrence in Case 4.
The patient responded well to the therapy and achieved
long, overall survival, 21 months, despite his advanced
stage. The three-year disease-free survival rate was
64.3%, and the three-year overall survival rate was 83.8%
after surgery.Discussion
NECs are classified into pure tumors and composite
tumors admixing adenocarcinomatous differentiation [1,2].
Criteria for classification in NEC categories is that over
30% of the cells display the features of neuroendocrine dif-
ferentiation [2]. NECs have aggressive biological behavior
and exhibit rapid proliferation. [1-7]primary tumor and metastatic lymph nodes









SE SYN CGA CD56 NSE
+ SC 3+ - 3+ 3+ 60 60 to 70
+ LC 1+ 3+ 1+ 2+ 20 20
+ 80 80 to 90
LC 3+ 3+ 2+ - 30 80 to 90
LC 3+ - 3+ - 70 100 to 110
+ pure Ad 2+ - - - 70 20
LC +Ad 3+ 2+ 1+ -
+ 80 100 to 110
and 3+ (over 50%). Ad, adenocarcinoma; CGA, chromogranin A; HPF, high
physin.
Figure 1 Immunohistochemical expression for neuroendocrine markers in primary tumor (Case 1). a) Synaptophysin, b) chromogranin A,
c) CD56, d) neuron-specific enolase. Tumor cells variably expressed neuroendocrine markers.
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pathological and immunohistochemical examination of
both the primary sites and metastatic lymph nodes. In this
study, we found an admixed population of pure neuroen-
docrine cells, adenocarcinoma cells and their intermediate
cells that have the morphological features of adenocarcin-
oma with positivity to neuroendocrine markers. Other
studies have reported that NEC shows strong staining for
neuroendocrine markers, such as CGA, SYN, NSE and
CD56 [1-3,5,7]. In our series, the positivity rate for CGA,
SYN, NSE and CD56 was 42.9%, 100%, 85.7% and 72.7%,
respectively. Among these markers, tumors showed theFigure 2 Immunohistochemical expression for neuroendocrine marke
Synaptophysin, b) chromogranin A, c) CD56, d) neuron-specific enolase. Ex
were similar to those in the primary tumor.highest positivity for SYN and lowest positivity for CGA.
CGA is a marker for neuroendocrine granules and an in-
dicative factor of differentiation to neuroendocrine cells.
The poor differentiation in our cases prevented sufficient
expression of granules.
We found that the tumors varied in immunohistochem-
ical expression. In one tumor, while some cells with high
CGA expression showed negativity for other markers,
some cells with no CGA expression showed diffuse high
positivity for other markers. In addition, besides neuroen-
docrine cells positive for SYN, some adenocarcinoma cells
showed positivity for SYN among composite-type tumors.rs in metastatic tumor cells in lymph nodes (Case 1). a)
pression patterns of neuroendocrine markers in metastatic tumors
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tinuity between the adenocarcinoma component and the
NEC component.
Furthermore, focusing on lymph nodes, we found that
cases with pure neuroendocrine primary sites had meta-
static lymph nodes with pure neuroendocrine cells
(Table 3). The variation in immunohistochemical expres-
sion patterns of the primary site was maintained even in
the metastatic pure endocrine cells. In Case 6, one of the
two cases with combined primary tumors, composite me-
tastasis of NEC and adenocarcinoma was seen in some
lymph nodes, and pure adenocarcinoma metastasis was
seen in other nodes. The tumor showed consistency in
both histological type and immunohistochemical expres-
sion between the primary site and the metastatic lymph
nodes. This result led to a hypothesis as to the manner of
metastasis. That is, clustered cells, including adenocarcin-
oma and neuroendocrine cells with varied immunopheno-
types, spread to the lymph nodes and coexisted there.
Additionally, lymph nodes of composite-type tumors
expressed a slightly different staining pattern. Cells not
undergoing sufficiently mature differentiation in primary
sites may differentiate into neuroendocrine cells or de-
velop varied immunohistochemical expression. In this
series, there was no clear association between immunohis-
tochemical expression and clinical outcome. Cases with
low Ki67 labeling indices had a good prognosis. For ex-
ample, Case 2, for which the Ki67 labeling index was 20%,
achieved the longest survival term, 55 months. Case 4, for
which the Ki67 labeling index was 30%, was successfully
treated with surgery and chemotherapy and survived for
21 months despite distant metastasis. Limitations of this
study include short duration of follow-up and small sam-
ple size mostly composed of pure types. Therefore, large-
scale and long-term studies are needed to draw a defini-
tive conclusion.Conclusion
In summary, we reported the pathological and immuno-
histochemical features of neuroendocrine carcinomas at
both the primary sites and metastatic lymph nodes. The
cells grow rapidly and metastasize to the lymph nodes
retaining their heterogeneity even at the metastatic sites.Abbreviations
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